FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973.
about
Integration of Mitochondrial Targeting for Molecular Cancer TherapeuticsImmune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNγ.Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis.The enhanced in vivo activity of the combination of a MEK and a PI3K inhibitor correlates with [18F]-FLT PET in human colorectal cancer xenograft tumour-bearing mice.Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [(18)F] FDG-PET imaging combined with proteomic approaches.BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume.Evaluation of the therapeutic efficacy of a MEK inhibitor (TAK-733) using ¹⁸F-fluorodeoxyglucose-positron emission tomography in the human lung xenograft model A549.Correlation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanomaMetabolic Activity by 18F-FDG-PET/CT Is Prognostic for Stage I and II Pancreatic CancerGlucose transporter isoform 1 expression enhances metastasis of malignant melanoma cellsActionable Intelligence Provided by Pancreatic Cancer Genomic Landscape: Are Targets for Curative Therapy On The Map?It takes two to tango--signalling by dimeric Raf kinases.Putative role of HIF transcriptional activity in melanocytes and melanoma biology.Towards combinatorial targeted therapy in melanoma: from pre-clinical evidence to clinical application (review).Targeting T cell metabolism for therapy.Cobimetinib: First Global Approval.Disruption of mitochondrial electron transport chain function potentiates the pro-apoptotic effects of MAPK inhibition.Overexpression of pyruvate dehydrogenase kinase supports dichloroacetate as a candidate for cutaneous melanoma therapy.Therapy response monitoring of the early effects of a new BRAF inhibitor on melanoma xenograft in mice: evaluation of (18) F-FDG-PET and (18) F-FLT-PET.MR-detectable metabolic consequences of mitogen-activated protein kinase kinase (MEK) inhibition.Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy.Increased Expression of the Glucose Transporter Type 1 Gene Is Associated With Worse Overall Survival in Resected Pancreatic Adenocarcinoma.18F-FDG-PET/CT and diffusion-weighted MRI for monitoring a BRAF and CDK 4/6 inhibitor combination therapy in a murine model of human melanoma.[Response evaluation in nuclear medicine : Criteria, results and pitfalls].Pivotal role of NAMPT in the switch of melanoma cells toward an invasive and drug-resistant phenotype.Imaging of molecular target modulation in oncology: challenges of early clinical trials
P2860
Q26771751-FBF787D7-E35E-461F-96F8-6E130101F1FAQ33776925-D9C1CF48-355D-4099-B41C-6C4073E7CECDQ33946905-98D17C4C-2064-45BB-8098-ABB65C81A742Q35067622-DD23AD29-2479-4674-8427-CFF600B2C2BAQ35675442-67C46F71-8FCA-4399-B1FC-EE1477C6E9D7Q35836409-DB443EF0-F553-4B95-966C-9E1219FE3D48Q35921493-174827E5-C34D-410E-9A94-7EF4C8F782F7Q36399789-53D3CA56-87E3-477D-94DC-D63361842673Q36540475-8790D758-B094-4580-A7E1-B6F9087E364FQ36544964-541C7102-2453-45FF-A092-6D2DA2C0736CQ37265792-5159DA7F-3B05-4998-AA41-90F9246E2AA5Q38065119-264F0295-B8F8-4523-863C-75A9DD987A5EQ38160223-C09D3D5B-84D8-4475-BA87-2B02222B36A1Q38219616-977371F5-FD43-44D3-961F-CD9D3CEA203CQ38324388-22A4166C-C4CF-4788-B985-C75C681AC96BQ38603243-98179DA1-3B56-4E9F-B5E6-D5CBE5949233Q38702202-DDF78D46-7A8B-40C7-83C6-B615C663FC31Q38874710-F6DDE095-1769-4E64-8123-4BDE2D04E1A6Q38958115-0C7B3A3D-F0C7-4CF7-B3B5-6A9244B8FE92Q39007170-03ADE4F3-D6F0-4004-88C9-9C63BF8818FEQ39418546-43313EE9-78B6-49B8-912B-5C5067C28BDDQ40182987-ADD59A22-B3A9-48F9-B6FF-941979483464Q49770136-58426D64-75D4-4C78-BD2D-170BA2CC58A8Q50218104-BC7FDF97-9B49-4EF1-AFB6-35848C694932Q51760444-C8BF458C-8394-4D29-A0AC-FAF41DDDB8D4Q57758791-EB19FC0E-9E8B-4A65-909A-96E6DB081E87
P2860
FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
FDG-PET is a good biomarker of ...... nd the MEK inhibitor GDC-0973.
@en
FDG-PET is a good biomarker of ...... nd the MEK inhibitor GDC-0973.
@nl
type
label
FDG-PET is a good biomarker of ...... nd the MEK inhibitor GDC-0973.
@en
FDG-PET is a good biomarker of ...... nd the MEK inhibitor GDC-0973.
@nl
prefLabel
FDG-PET is a good biomarker of ...... nd the MEK inhibitor GDC-0973.
@en
FDG-PET is a good biomarker of ...... nd the MEK inhibitor GDC-0973.
@nl
P2093
P2860
P356
P1433
P1476
FDG-PET is a good biomarker of ...... nd the MEK inhibitor GDC-0973.
@en
P2093
Andreas R Baudy
Judith E Flores-Mercado
Klaus P Hoeflich
Nicholas van Bruggen
Simon-Peter Williams
Taner Dogan
P2860
P2888
P356
10.1186/2191-219X-2-22
P577
2012-05-31T00:00:00Z
P5875
P6179
1040377561